Armata Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Armata Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Armata Pharmaceuticals Inc recorded a cumulative net loss of $-283 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -347.32%.

However, within the Healthcare sector 896 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4580, from total ROA ranking in the first quarter of 2026 at 5197.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	11.34 %	-20 %	66.07 %	55 %	20.36 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-283	-283	-174	-47	-26
Return On Assets (TTM)	-347.32 %	-356.62 %	-207.87 %	-61.74 %	-37.79 %
ARMP's Total Ranking	# 4580	# 5197	# 4066	# 3763	# 2649
Total Assets (TTM) in million	90	70	77	90	81
Seq. Total Assets Change	28.87 %	-9.21 %	-14.11 %	10.8 %	-7.4 %
Seq. Net Income Change	-	-	-	-	-

ARMP's 5 Years Annual ROA >> Back to ARMP Management Effectiveness >> Compare ARMP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 139
Sector	# 897
Overall	# 4525

Return On Assets Statistics
High	Average	Low
143.37 %	-61.26 %	-356.62 %
(Dec 31 2014)		(Mar 31 2026)

Financial Statements
Armata Pharmaceuticals Inc 's Assets	$ 90 million	ARMP's Balance sheet
Armata Pharmaceuticals Inc 's Income	$ -17 million	Quarterly ARMP's Income Statement
ARMP's Income by Division		See ARMP's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	66.07 %	-16.52 %	3.83 %	48.52 %	17.37 %
Total Assets in million	77	46	55	53	36
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-174	-19	-69	-37	-23
Annual Return On Assets	-226.06 %	-40.86 %	-124.5 %	-69.12 %	-64.39 %

ARMP's 5 Years Annual ROA >> Back to ARMP Management Effectiveness >> Compare ARMP ROA to its Competitors

More Return On Assets Ratios
ARMP's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARMP's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARMP's Competitors
Subscribers only: Roa for Armata Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ARMP's Customers

You may also want to know
ARMP's Roi	ARMP's Inventory Turnover Ratio	ARMP's Growth Rates	ARMP's Dividend Comparisons
	ARMP's Profitability Ratios	ARMP's Asset Turnover Ratio	ARMP's Dividend Growth
ARMP's Roe	ARMP's Valuation Ratios	ARMP's Financial Strength Ratios	ARMP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-04T10:01:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.